Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 4/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 10/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.34 |
| ▸ | IDH1 | O75874 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL4932708 | 0.93 | OPRL1 (0.41) | OPRL1MCHR1ADRA1ANPY5R | |
| SCHEMBL4935988 | 0.90 | OPRL1 (0.47) | OPRL1MCHR1ADRA1ANPY5RHRH3 | |
| SCHEMBL4900212 | 0.90 | OPRL1 (0.36) | OPRL1MCHR1ADRA1ANAMPT | |
| SCHEMBL4898569 | 0.89 | OPRL1 (0.36) | OPRL1MCHR1ADRA1AIDH1NAMPT | |
| SCHEMBL4936588 | 0.88 | OPRL1 (0.53) | OPRL1MCHR1ADRA1ANAMPT | |
| SCHEMBL4947330 | 0.85 | OPRL1 (0.44) | OPRL1MCHR1ADRA1AIDH1NAMPT | |
| SCHEMBL4977771 | 0.84 | OPRL1 (0.65) | OPRL1MCHR1ADRA1A | |
| Citric Acid SCHEMBL4936359 | 0.83 | OPRL1 (0.42) | OPRL1MCHR1ADRA1ANPY5RHRH3 | |
| Citric Acid SCHEMBL4932379 | 0.82 | OPRL1 (0.47) | OPRL1MCHR1ADRA1A | |
| SCHEMBL4939794 | 0.82 | OPRL1 (0.56) | OPRL1MCHR1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200490-A1 | Alpha-(Aryl-or Heteroaryl-Methyl)-Beta-Piperidino Propanamide Compounds as Orl-1-Receptor Antagonists | PFIZER INC. | 2008-08-21 | — | — | US | claimed |
| US-20080200490-A1 | Alpha-(Aryl-or Heteroaryl-Methyl)-Beta-Piperidino Propanamide Compounds as Orl-1-Receptor Antagonists | PFIZER INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080200490-A1 | Alpha-(Aryl-or Heteroaryl-Methyl)-Beta-Piperidino Propanamide Compounds as Orl-1-Receptor Antagonists | PFIZER INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080200490-A1 | Alpha-(Aryl-or Heteroaryl-Methyl)-Beta-Piperidino Propanamide Compounds as Orl-1-Receptor Antagonists | PFIZER INC. | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200490-A1 | Alpha-(Aryl-or Heteroaryl-Methyl)-Beta-Piperidino Propanamide Compounds as Orl-1-Receptor Antagonists | OPRL1, OPRD1, OGFRL1 | OPRL1 1/4885MCHR1 336/4885ADRA1A 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.